The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
Clinical trial NCT06616727 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06616727
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-26
- Primary completion
- 2024-12-31
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.